Karmanos Cancer Hospital
- Type
- Teaching hospital
- Where
- Detroit, MI
- Medicare CCN
- 230297
- Received
- $13,322,223 in 2,675 records, 2020 ($17,059 general, $13,305,163 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 5 | $17,059 |
| 2020 | Research payment | 2,670 | $13,305,163 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 2,670 | $13,305,163 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 5 | $17,059 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $14,927 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combinatio | 2020 |
| 2020-12-31 | CSL Behring | $9,088 | Research payment | Cash or cash equivalent | Zemaira Biological, Pulmonary/Respiratory Diseases | A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With | 2020 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $5,952 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co | 2020 |
| 2020-12-31 | Alkermes, Inc. | $4,410 | Research payment | In-kind items and services | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i | 2020 | |
| 2020-12-31 | Janssen Research & Development, LLC | $1,799 | Research payment | Cash or cash equivalent | A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Rep | 2020 | |
| 2020-12-31 | Genentech, Inc. | $1,500 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2020 |
| 2020-12-31 | Genentech, Inc. | $1,320 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2020 |
| 2020-12-31 | Genentech, Inc. | $1,320 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2020 |
| 2020-12-31 | Genentech, Inc. | $1,320 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | PH1B 2 TDB POLA DOSE ESCALATION IN R R NHL PH1B FOLLOWED BY EXPANSION IN R R DLBCL AND R R FL PH2 | 2020 |
| 2020-12-31 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $779 | Research payment | In-kind items and services | Ph2a Montherapy RCC study | 2020 | |
| 2020-12-31 | Janssen Research & Development, LLC | $650 | Research payment | Cash or cash equivalent | A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $67 | Research payment | In-kind items and services | Study of MEDI4736 Durvalumab With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $3 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | This is a non randomized open label study to assess olaparib tablets as a treatment for subjects with different homologo | 2020 |
| 2020-12-29 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r | 2020 |
| 2020-12-29 | Merck Sharp & Dohme LLC | $10,539 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu | 2020 |
| 2020-12-29 | Merck Sharp & Dohme LLC | $2,556 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrol | 2020 |
| 2020-12-29 | Amgen Inc. | $1,490 | Research payment | Cash or cash equivalent | Blincyto Biological, Oncology | An OR study of patients with Relapsed/Refractory Acute Lymphoblastic Leukemia in the US - Serial CR | 2020 |
| 2020-12-24 | Alkermes, Inc. | $15,787 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-24 | Alkermes, Inc. | $15,787 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-24 | Alkermes, Inc. | $15,787 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-24 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-24 | Alkermes, Inc. | $3,100 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-24 | Alkermes, Inc. | $3,100 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-24 | Alkermes, Inc. | $3,100 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-24 | Alkermes, Inc. | $322 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-24 | Daiichi Sankyo Inc. | $69 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-12-23 | SEAGEN INC. | $429 | Research payment | Cash or cash equivalent | ADCETRIS Biological, Oncology | A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory H | 2020 |
| 2020-12-23 | SEAGEN INC. | $231 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in o | 2020 | |
| 2020-12-22 | SEAGEN INC. | $27,456 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | 2020 | |
| 2020-12-22 | ABBVIE INC. | $2,647 | Research payment | Cash or cash equivalent | M19-894 | 2020 | |
| 2020-12-22 | Merck Sharp & Dohme LLC | $2,500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do | 2020 |
| 2020-12-22 | ABBVIE INC. | $2,000 | Research payment | Cash or cash equivalent | M19-894 | 2020 | |
| 2020-12-22 | Incyte Corporation | $1,599 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2020 | |
| 2020-12-22 | Bayer Healthcare Pharmaceuticals Inc. | $1,500 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-9343 Solid Tumor Multi Cohort Trial | 2020 |
| 2020-12-22 | Bayer Healthcare Pharmaceuticals Inc. | $1,320 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-9343 Solid Tumor Multi Cohort Trial | 2020 |
| 2020-12-22 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2020 | |
| 2020-12-22 | Bayer Healthcare Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | Non-Covered | BAY94-9343 Solid Tumor Multi Cohort Trial | 2020 |
| 2020-12-21 | Janssen Research & Development, LLC | $6,102 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, | 2020 | |
| 2020-12-21 | BIOVERATIV THERAPEUTICS INC. | $4,559 | Research payment | Cash or cash equivalent | A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for A | 2020 | |
| 2020-12-21 | BIOVERATIV THERAPEUTICS INC. | $1,320 | Research payment | Cash or cash equivalent | A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for A | 2020 | |
| 2020-12-21 | Genentech, Inc. | $1,171 | Research payment | Cash or cash equivalent | Drug | PHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE | 2020 |
| 2020-12-21 | Merck Sharp & Dohme LLC | $579 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu | 2020 |
| 2020-12-18 | Merck Sharp & Dohme LLC | $32,569 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu | 2020 |
| 2020-12-18 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subject | 2020 | |
| 2020-12-18 | Janssen Research & Development, LLC | $1,320 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subject | 2020 | |
| 2020-12-18 | Genentech, Inc. | $894 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | NEOADJUVANT NSCLC | 2020 |
| 2020-12-18 | Janssen Research & Development, LLC | $750 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2020 | |
| 2020-12-18 | Merck Sharp & Dohme LLC | $426 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrol | 2020 |
| 2020-12-18 | Janssen Research & Development, LLC | $200 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Dose Escalation Study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in Subject | 2020 | |
| 2020-12-18 | Merck Sharp & Dohme LLC | $29 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatini | 2020 |
| 2020-12-17 | Alkermes, Inc. | $319,398 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-17 | Alkermes, Inc. | $16,120 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-17 | Alkermes, Inc. | $15,787 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-17 | Alkermes, Inc. | $15,787 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-17 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-17 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-17 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-17 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-17 | Pharmacyclics LLC, an AbbVie Company | $8,600 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-12-17 | Janssen Research & Development, LLC | $7,456 | Research payment | Cash or cash equivalent | A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA | 2020 | |
| 2020-12-17 | Exelixis Inc. | $6,239 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-12-17 | Takeda Pharmaceuticals U.S.A., Inc. | $5,346 | Research payment | Cash or cash equivalent | A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULT | 2020 | |
| 2020-12-17 | Exelixis Inc. | $3,800 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-12-17 | Pharmacyclics LLC, an AbbVie Company | $3,700 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-12-17 | Alkermes, Inc. | $3,100 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-17 | Alkermes, Inc. | $3,100 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-17 | Alkermes, Inc. | $3,100 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-17 | ABBVIE INC. | $2,953 | Research payment | Cash or cash equivalent | M19-894 | 2020 | |
| 2020-12-17 | Alkermes, Inc. | $2,791 | Research payment | Cash or cash equivalent | A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and i | 2020 | |
| 2020-12-17 | Alkermes, Inc. | $2,522 | Research payment | In-kind items and services | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-17 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS | 2020 |
| 2020-12-17 | Merck Sharp & Dohme LLC | $1,126 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrol | 2020 |
| 2020-12-17 | Alkermes, Inc. | $1,000 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-17 | Regeneron Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2020 | |
| 2020-12-17 | TAIHO ONCOLOGY, INC. | $1,000 | Research payment | Cash or cash equivalent | TAS-120 | 2020 | |
| 2020-12-17 | Exelixis Inc. | $858 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-12-17 | Regeneron Pharmaceuticals, Inc. | $755 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2020 | |
| 2020-12-17 | Alkermes, Inc. | $591 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-17 | Regeneron Pharmaceuticals, Inc. | $400 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2020 | |
| 2020-12-17 | TAIHO ONCOLOGY, INC. | $224 | Research payment | Cash or cash equivalent | TAS-120 | 2020 | |
| 2020-12-17 | Alkermes, Inc. | $83 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-16 | Merck Sharp & Dohme LLC | $10,480 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase I,II Study of MK-3475 SCH900475 in Combination with Chemotherapy and,or Immunotherapy in Patients with Locally A | 2020 |
| 2020-12-16 | SEAGEN INC. | $1,000 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in o | 2020 | |
| 2020-12-16 | Merck Sharp & Dohme LLC | $237 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2020 |
| 2020-12-15 | Merck Sharp & Dohme LLC | $27,650 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r | 2020 |
| 2020-12-15 | GlaxoSmithKline, LLC. | $11,768 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF DOSTARLIMAB | 2020 | |
| 2020-12-15 | Takeda Pharmaceuticals U.S.A., Inc. | $8,307 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS (PK) OF TAK-981 IN ADULT PARTICIPANTS WITH ADVANCED OR | 2020 | |
| 2020-12-15 | Merck Sharp & Dohme LLC | $2,200 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 3, Randomized, Open-label Study of Pembrolizumab MK-3475 Plus Olaparib Versus Abiraterone Acetate or Enzalutamid | 2020 |
| 2020-12-15 | Takeda Pharmaceuticals U.S.A., Inc. | $1,568 | Research payment | Cash or cash equivalent | ICLUSIG Drug, ONCOLOGY | A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA T | 2020 |
| 2020-12-15 | Regeneron Pharmaceuticals, Inc. | $1,500 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2020 |
| 2020-12-15 | Regeneron Pharmaceuticals, Inc. | $990 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2020 |
| 2020-12-15 | Regeneron Pharmaceuticals, Inc. | $660 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2020 |
| 2020-12-15 | Regeneron Pharmaceuticals, Inc. | $660 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2020 |
| 2020-12-15 | Clovis Oncology, Inc. | $429 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, Hi | 2020 |
| 2020-12-15 | Exelixis Inc. | $400 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-12-15 | Regeneron Pharmaceuticals, Inc. | $300 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2020 |
| 2020-12-15 | Immunomedics, Inc. | $55 | Research payment | Cash or cash equivalent | Trodelvy Drug, Oncology | IMMU-132-11 | 2020 |
| 2020-12-14 | Genentech, Inc. | $5,265 | Research payment | Cash or cash equivalent | Drug | PHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE | 2020 |
| 2020-12-14 | Janssen Research & Development, LLC | $2,500 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, | 2020 | |
| 2020-12-14 | Janssen Research & Development, LLC | $2,181 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, | 2020 | |
| 2020-12-14 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, | 2020 | |
| 2020-12-14 | Janssen Research & Development, LLC | $1,320 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, | 2020 | |
| 2020-12-14 | Janssen Research & Development, LLC | $1,000 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, | 2020 | |
| 2020-12-14 | Janssen Research & Development, LLC | $677 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, | 2020 | |
| 2020-12-14 | Janssen Research & Development, LLC | $400 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, | 2020 | |
| 2020-12-14 | Janssen Research & Development, LLC | $130 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, | 2020 | |
| 2020-12-14 | Janssen Research & Development, LLC | $56 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, | 2020 | |
| 2020-12-10 | Daiichi Sankyo Inc. | $5,765 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-12-10 | Janssen Research & Development, LLC | $4,334 | Research payment | Cash or cash equivalent | A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA | 2020 | |
| 2020-12-10 | Janssen Research & Development, LLC | $3,681 | Research payment | Cash or cash equivalent | A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA | 2020 | |
| 2020-12-10 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | 2020 | |
| 2020-12-10 | Pharmacyclics LLC, an AbbVie Company | $1,215 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1123-CA | 2020 |
| 2020-12-10 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refracto | 2020 |
| 2020-12-10 | Janssen Research & Development, LLC | $650 | Research payment | Cash or cash equivalent | A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | 2020 | |
| 2020-12-09 | Radius Health, Inc. | $13,040 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Canc | 2020 | |
| 2020-12-09 | Genentech, Inc. | $3,150 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | A PHASE III TRIAL IN ADJUVANT HER2 BC PTS | 2020 |
| 2020-12-09 | SEAGEN INC. | $1,000 | Research payment | Cash or cash equivalent | A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies | 2020 | |
| 2020-12-09 | SEAGEN INC. | $1,000 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in o | 2020 | |
| 2020-12-09 | Genentech, Inc. | $1,000 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | TECENTRIQ ONCOLOGY EXTENSION STUDY | 2020 |
| 2020-12-09 | SEAGEN INC. | $1,000 | Research payment | Cash or cash equivalent | A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies | 2020 | |
| 2020-12-09 | Alkermes, Inc. | $757 | Research payment | In-kind items and services | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-09 | Alkermes, Inc. | $518 | Research payment | In-kind items and services | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-12-09 | Merck Sharp & Dohme LLC | $381 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase II,III Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with | 2020 |
| 2020-12-08 | Genentech, Inc. | $29,362 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | NEOADJUVANT NSCLC | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | $27,650 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r | 2020 |
| 2020-12-08 | Regeneron Pharmaceuticals, Inc. | $2,649 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2020 |
| 2020-12-08 | Regeneron Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C | 2020 |
| 2020-12-07 | Merck Sharp & Dohme LLC | $305 | Research payment | In-kind items and services | MK-7684 Drug, ONCOLOGY | Phase I Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumor | 2020 |
| 2020-12-04 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-r | 2020 |
| 2020-12-04 | Janssen Research & Development, LLC | $9,851 | Research payment | Cash or cash equivalent | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, | 2020 | |
| 2020-12-04 | Merck Sharp & Dohme LLC | $1,500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemother | 2020 |
| 2020-12-04 | Geistlich Pharma, North America, Inc. | $755 | Research payment | Cash or cash equivalent | Phase 1/2 Trial to Evaluate the safety, tolerability, Pharmacokinetics and preliminary efficacy of GP-2250 in combinatio | 2020 | |
| 2020-12-03 | Daiichi Sankyo Inc. | $60,027 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-12-03 | Daiichi Sankyo Inc. | $3,301 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-12-03 | BIOVERATIV THERAPEUTICS INC. | $2,640 | Research payment | Cash or cash equivalent | A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for A | 2020 | |
| 2020-12-03 | Daiichi Sankyo Inc. | $2,232 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-12-03 | Pharmacyclics LLC, an AbbVie Company | $1,569 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1143-CA | 2020 |
| 2020-12-03 | Pharmacyclics LLC, an AbbVie Company | $1,500 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1140-IM | 2020 |
| 2020-12-03 | Pharmacyclics LLC, an AbbVie Company | $1,320 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1140-IM | 2020 |
| 2020-12-03 | Daiichi Sankyo Inc. | $1,000 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-12-03 | BeiGene, Ltd. | $1,000 | Research payment | Cash or cash equivalent | BRUKINSA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine | 2020 |
| 2020-12-03 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2020 |
| 2020-12-03 | Pharmacyclics LLC, an AbbVie Company | $990 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1140-IM | 2020 |
| 2020-12-03 | Daiichi Sankyo Inc. | $942 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-12-03 | Daiichi Sankyo Inc. | $755 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-12-03 | Janssen Research & Development, LLC | $750 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2020 | |
| 2020-12-03 | Daiichi Sankyo Inc. | $678 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-12-03 | Daiichi Sankyo Inc. | $524 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-12-03 | Daiichi Sankyo Inc. | $400 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-12-03 | Daiichi Sankyo Inc. | $400 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-12-03 | Daiichi Sankyo Inc. | $230 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-12-03 | Daiichi Sankyo Inc. | $186 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-12-03 | Daiichi Sankyo Inc. | $91 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-12-03 | Daiichi Sankyo Inc. | $41 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-12-02 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemother | 2020 |
| 2020-12-02 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab MK-3475 Plus Chemotherapy Versus Chemother | 2020 |
| 2020-12-01 | Merck Sharp & Dohme LLC | $21,600 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb 22841 Monotherapy and in Combination with | 2020 |
| 2020-12-01 | Merck Sharp & Dohme LLC | $6,950 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with | 2020 |
| 2020-12-01 | Immunomedics, Inc. | $2,999 | Research payment | Cash or cash equivalent | Trodelvy Drug, Oncology | IMMU-132-11 | 2020 |
| 2020-12-01 | AstraZeneca UK Limited | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2020 | |
| 2020-12-01 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500 | Research payment | Cash or cash equivalent | ALUNBRIG Drug, ONCOLOGY | BRIGATINIB IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+), ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PROG | 2020 |
| 2020-12-01 | Takeda Pharmaceuticals U.S.A., Inc. | $1,320 | Research payment | Cash or cash equivalent | ALUNBRIG Drug, ONCOLOGY | BRIGATINIB IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+), ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PROG | 2020 |
| 2020-12-01 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2020 |
| 2020-12-01 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2020 |
| 2020-12-01 | AstraZeneca UK Limited | $618 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2020 | |
| 2020-12-01 | Immunomedics, Inc. | $154 | Research payment | Cash or cash equivalent | Trodelvy Drug, Oncology | IMMU-132-11 | 2020 |
| 2020-11-30 | Merck Sharp & Dohme LLC | $5,656 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrol | 2020 |
| 2020-11-30 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2020 |
| 2020-11-30 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu | 2020 |
| 2020-11-30 | Janssen Research & Development, LLC | $975 | Research payment | Cash or cash equivalent | A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study | 2020 | |
| 2020-11-27 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus | 2020 |
| 2020-11-27 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus | 2020 |
| 2020-11-27 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus | 2020 |
| 2020-11-26 | Alkermes, Inc. | $25,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-11-26 | Alkermes, Inc. | $23,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-11-26 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-11-26 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-11-26 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-11-26 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-11-26 | Alkermes, Inc. | $15,710 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-11-26 | Alkermes, Inc. | $3,100 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-11-26 | Alkermes, Inc. | $3,100 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-11-26 | Alkermes, Inc. | $3,100 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-11-26 | Alkermes, Inc. | $3,100 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-11-26 | Alkermes, Inc. | $2,800 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-11-26 | Alkermes, Inc. | $2,399 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-11-26 | Regeneron Pharmaceuticals, Inc. | $2,181 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2020 | |
| 2020-11-26 | Regeneron Pharmaceuticals, Inc. | $1,500 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2020 | |
| 2020-11-26 | Daiichi Sankyo Inc. | $1,500 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | 2020 | |
| 2020-11-26 | Regeneron Pharmaceuticals, Inc. | $1,320 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2020 | |
| 2020-11-26 | Alkermes, Inc. | $1,000 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-11-26 | Regeneron Pharmaceuticals, Inc. | $400 | Research payment | Cash or cash equivalent | PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTI | 2020 | |
| 2020-11-26 | Alkermes, Inc. | $243 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-11-26 | Alkermes, Inc. | $142 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-11-26 | Alkermes, Inc. | $142 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-11-26 | Alkermes, Inc. | $23 | Research payment | Cash or cash equivalent | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | 2020 | |
| 2020-11-25 | AstraZeneca UK Limited | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2020 | |
| 2020-11-25 | Novocure Inc. | $1,730 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-25 Pivotal, oopen-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 | 2020 |
| 2020-11-25 | Novocure Inc. | $1,080 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-25 Pivotal, oopen-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 | 2020 |
The latest 200 records of 2,675.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Detroit, MI, county Wayne County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Detroit, MI | County Wayne County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 638,530 | 1,772,259 | 10,077,761 |
| Population, 2020 census P1 | 639,111 | 1,793,561 | 10,077,331 |
| Median age B01002 | 35.2 | 37.9 | 40.2 |
| Under 18 B01001 | 24.8% | 23.6% | 21.2% |
| 65 and over B01001 | 15.1% | 16.6% | 18.6% |
| Households B11001 | 257,998 | 700,591 | 4,076,369 |
| Foreign born B05002 | 6.6% | 10.3% | 7.2% |
| Median household income B19013 | $39,938 | $60,539 | $72,875 |
| Median family income B19113 | $49,398 | $79,522 | $93,357 |
| Per capita income B19301 | $24,594 | $34,906 | $40,735 |
| Poverty rate B17001 | 32.7% | 20.8% | 13.2% |
| Unemployment rate B23025 | 14.0% | 8.7% | 5.7% |
| Civilian labor force B23025 | 268,955 | 828,838 | 5,018,449 |
| Mean commute (minutes) B08013 | 24.8 | 24.7 | 24.2 |
| Bachelor's degree or higher B15003 | 18.1% | 27.6% | 32.4% |
| Housing units B25001 | 329,393 | 801,083 | 4,622,236 |
| Owner-occupied B25003 | 50.3% | 64.8% | 73.2% |
| Renters B25003 | 49.7% | 35.2% | 26.8% |
| Median home value B25077 | $83,900 | $178,500 | $231,600 |
| Median gross rent B25064 | $1,074 | $1,132 | $1,129 |
| White, not Hispanic B03002 | 10.8% | 47.9% | 72.4% |
| Black B03002 | 75.0% | 36.6% | 13.1% |
| Hispanic or Latino B03002 | 8.3% | 6.9% | 5.9% |
| Asian B03002 | 1.7% | 3.7% | 3.4% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Detroit, MI.
Comments